FDA panel backs new Alzheimer’s drug, despite risks and uncertainties

Pivotal trial of Eli Lilly’s donanemab leaves questions about how to prescribe it and minimize side effectsPivotal trial of Eli Lilly’s donanemab leaves questions about how to prescribe it and minimize side effects Read More